Recommendation 2

     

Recommendation 2Produce and implement clinical guidelines and pathways for  testing,  improved diagnosis and management of cCMV.

Paediatricians and other professionals working with families must understand the guidelines for managing CMV so that more families receive monitoring and support. 

As the estimated costs for acute antiviral treatment are relatively minor, more research needs to be conducted to assess whether antiviral treatment can be effective in preventing or reducing the severity of other forms of impairment that develop as a consequence of cCMV.

There is evidence to show that the antiviral medicine valganciclovir is effective at reducing SNHL, as well as developmental delays in other neurocognitive functions, in the 24 months following birth.

Given that a high proportion of the cost burden is attributable to babies born without symptoms, who later develop neurodevelopmental impairments. More research into the benefits of this treatment in babies presenting with no symptoms may provide another avenue from which to target the cost burden of the virus.  It is only through this that we will be able to bring the UK in line with other countries more advanced in managing CMV infection. 

 

     

Our Stories

Alfie-CMV-Story
I wanted to share my CMV story, this is my wonderful little boy Alfie. I had a normal pregnancy and labour, I had Alfie at 11.30 at night and the next morning got him ready to take home... Read more
It all started on the day of my 20 week scan which was also the day of my 20th birthday, the worst day of my life. I never had any worries as I had a straightforward 12... Read more

Latest Events

Registered charity no: 1171773